VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

VBL Ther­a­peu­tics an­nounced that it is on track in a Phase III tri­al of its drug VB-111 (ofran­er­gene obade­n­ovec) to treat plat­inum-re­sis­tant ovar­i­an can­cer in com­bi­na­tion with pa­cli­tax­el.

Af­ter con­duct­ing its sec­ond in­ter­im analy­sis, the in­de­pen­dent Da­ta Safe­ty Mon­i­tor­ing Com­mit­tee (DSMC) rec­om­mend­ed that Is­rael-based VBL con­tin­ue full steam ahead. The com­mit­tee looked at un­blind­ed over­all sur­vival rate, which is the pri­ma­ry end­point of the study, dubbed OVAL. The first analy­sis eval­u­at­ed CA-125 re­sponse.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER